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Background: Oesophageal squamous cell carcinoma (OSCC) is a highly aggressive carcinoma with a poor survival
rate. One of the most commonly used chemotherapeutic drugs, cisplatin, displays varied and often poor efficacy
in vivo. Therefore, alternative, cost-effective and more efficacious treatments are required. Metformin has been
previously shown to reduce proliferative rates in various carcinoma cell lines. We report for the first time, the
effect of metformin on OSCC cell proliferation and show that it antagonises cisplatin-induced but not copper-bis
(thiosemicarbazone)-induced cytotoxicity in OSCC cells.
Methods: Cell proliferation and stage of the cell cycle were quantified by trypan blue counts and flow cytometry,
respectively. All cytotoxicity measurements were made using the tetrazolium based MTT assay. Metabolic
alterations to cells were determined as follows: glycolysis via a lactate dehydrogenase assay, reducing equivalents
by MTT reduction and reduced intracellular thiols by monobromobimane-thiol fluorescence, and glutathione
depletion using buthionine sulfoximine. Inductively coupled plasma mass spectrometry was used to quantify
cisplatin-DNA adduct formation.
Results: Metformin was found to reduce cell proliferation significantly in all OSCC cell lines, with an accumulation
of cells in G0/G1 phase of the cell cycle. However, metformin significantly protected OSCC cells against cisplatin
toxicity. Our results indicate that a major mechanism of metformin-induced cisplatin resistance results from a
significant increase in glycolysis, intracellular NAD(P)H levels with a concomitant increase in reduced intracellular
thiols, leading to decreased cisplatin-DNA adduct formation. The glutathione synthesis inhibitor buthionine
sulfoximine significantly ablated the protective effect of metformin. We subsequently show that the copper-bis
(thiosemicarbazones), Cu-ATSM and Cu-GTSM, which are trapped in cells under reducing conditions, cause significant
OSCC cytotoxicity, both alone and in combination with metformin.
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Conclusions: This is the first study showing that metformin can be used to decrease cell proliferation in OSCC cells.
However, metformin protects against cisplatin cytotoxicity by inducing a reducing intracellular environment
leading to lower cisplatin-DNA adduct formation. As such, we advise that caution be used when administering
cisplatin to diabetic patients treated with metformin. Furthermore, we propose a novel combination therapy
approach for OSCC that utilises metformin with metformin-compatible cytotoxic agents, such as the copper-bis
(thiosemicarbazones), Cu-ATSM and Cu-GTSM.
Keywords: Oesophageal squamous cell carcinoma, Metformin, Copper bis(thiosemicarbazones), Metabolism,
Cisplatin, Thiol, GlutathioneBackground
Oesophageal carcinoma, of which there are two sub-
types, adenocarcinoma and squamous cell carcinoma, is
the sixth most common cause of cancer-related death
[1]. Oesophageal squamous cell carcinoma (OSCC) is a
highly aggressive carcinoma with a very poor survival
rate that occurs with particularly high frequency in de-
veloping countries including Iran, China, South Africa,
and Brazil, where mortality rates can exceed 100 per
100,000 population. In developed countries, incidence
rarely exceeds 10 per 100,000 population [2,3], with the
exceptions of certain regions in North-West France and
Northern Italy where incidence may reach 30 and 2 per
100,000 in males and females, respectively [4]. The causes
of OSCC are multiple and varied, probably reflecting re-
peated exposure to dietary components, such as N-nitroso
compounds, excessive smoking and alcohol consumption,
chronic inflammation and possibly, genetic predisposition
[5]. Current commonly used therapies for OSCC include
5-fluorouracil and cisplatin, which show poor efficacy and
often display both chemotoxicity and chemoresistance [6].
Cisplatin has multiple mechanisms of cytotoxicity in-
cluding the formation of DNA and protein adducts,
as well as via oxidative stress. Many resistance mecha-
nisms for cisplatin have been identified, including, pertin-
ent to this study, sequestering of cisplatin by glutathione
(a major species of intracellular thiols). This results in
export of cisplatin-glutathione adducts leading to a
reduction in cisplatin-mediated DNA damage [7-9]. In-
vestigations into more effective targeted treatment op-
tions for OSCC using monoclonal antibody therapies
are very promising [10] however, access to such therap-
ies in developing countries is extremely limited, primar-
ily due to cost. Therefore, there is a continued and
urgent requirement for alternative, effective and eco-
nomical treatment options.
Recently, the well characterized and tolerated anti-
diabetic drug, metformin has been the subject of intense
investigations in cancer research. Population studies
have shown that this biguanide, conventionally used to
decrease peripheral glucose levels and increase insulin
sensitivity in diabetic and pre-diabetic patients [11,12],reduced breast cancer occurrence in female patients
with type 2 diabetes [13]. Since then, metformin has
been observed to reduce the proliferation of many types
of carcinoma cell lines and diabetic patients taking met-
formin have been found to have better recovery rates
from breast cancer [14-17]. Furthermore, metformin has
been shown to target cancer stem cells [18]. However,
whilst metformin reduces cell proliferation in most cancer
types, it rarely causes apoptosis, and is therefore being
combined with conventional chemotherapeutic drugs, in-
cluding cisplatin. This treatment combination has mixed
results, with some studies showing that metformin can en-
hance the effectiveness of chemotherapeutic drugs whilst
others have shown increased chemoresistance in the
presence of metformin [19,20]. With regards to cisplatin,
metformin has been shown to reduce cisplatin sensitivity
through the AMPK-independent upregulation of the Akt
survival pathway [20]. A search on clinicaltrials.gov found
over 40 clinical trials investigating metformin and a variety
of chemotherapeutic drugs, for breast, ovarian and pros-
tate cancer amongst a number of others.
In this study, we investigated the effect of metformin
on OSCC cell proliferation and on the cytotoxicity of
cisplatin for OSCC cells. We show that whilst metformin
markedly reduces OSCC cell proliferation and causes
cells to accumulate in the G0/G1 phase of the cell cycle,
it also significantly protects against cisplatin cytotoxicity.
The protective effect is not solely due to reduced cell-
proliferation, as the biguanide minimally to partially pro-
tects against the DNA-crosslinker, mitomycin C, but is
dependent on a metformin-induced increase in glycolysis
and intracellular NAD(P)H levels with a concomitant in-
crease in reduced intracellular thiols, which coincides
with decreased cisplatin-DNA adduct formation. The
glutathione synthesis inhibitor buthionine sulfoximine
(BSO) significantly reverses this protective effect, con-
firming the role of reduced glutathione in cisplatin
detoxification by metformin-treated cells. In light of
these findings, we investigated the copper-bis(thiosemi-
carbazones), copper diacetyl-bis(4-methylthiosemicar-
bazonato)copper(II) (Cu-ATSM) and copper glyoxal-bis
(4-methylthiosemicarbazonato)copper(II) (Cu-GTSM).
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a number of mechanisms, including inhibition of DNA
synthesis [21]. Importantly, as these compounds are
known to be trapped in cells under reducing conditions,
they are therefore compatible with a reducing intra-
cellular state [22]. We show that both Cu-ATSM and
Cu-GTSM display significant levels of cytotoxicity at
LD50 values comparable to or lower than cisplatin, both
alone or in combination with metformin, highlighting
the use of metformin and reduction-compatible cyto-
toxic drugs as a novel combination therapy strategy for
the treatment of OSCC.
Methods
Reagents
Reagents for flow cytometry were purchased from
Beckman Coulter. All other reagents were purchased
from Sigma Aldrich unless otherwise specified.
Synthesis of bis(thiosemicarbazones)
The bis(thiosemicarbazones), ATSM and GTSM, were
synthesised from 4-methyl thiosemicarbazide and butane-
dione or glyoxal, respectively, according to the method of
French et al. [23].
ATSM: 1H NMR (500 MHz, DMSO) 11.74 (2H, s, 2 ×
CH =N), 8.48 (2H, d, J = 4.2, 2 × NH), 7.72 (2H, s, 2 ×
NH), 2.96 (6H, d, J = 4.4, 2 × CH3);
13C NMR (126 MHz,
DMSO) 177.55 (2 × C = S), 140.02 (2 × C = N), 30.89
(2 × CH3).
GTSM: 1H NMR (500 MHz, DMSO) 10.20 (2H, s, 2 ×
NH), 8.36 (2H, d, J = 4.1, 2 × NH), 3.02 (6H, d, J = 4.5,
2 × CH3), 2.20 (6H, s, 2 × CH3);
13C NMR (126 MHz,
DMSO) 178.47 (2 × C = S), 147.95 (2 × C = N), 31.18
(2 × CH3), 11.64 (2 × CH3).
Cu-ATSM and Cu-GTSM were synthesized from
ATSM and GTSM and cupric chloride as previously
described [24].
Cell culture
The human OSCC cell lines were a kind gift from Pro-
fessor Robin Veale. These cells, WHCO1, WHCO5 [25]
and SNO [26] were maintained in Dulbecco’s Modified
Eagles Medium/Hams F12 (DMEM/Hams F12, 3:1) sup-
plemented with 10% FCS at 37°C and 5% CO2.
Cell proliferation
Cell proliferation was assessed by cell counts using try-
pan blue exclusion. Cells were seeded in 48-well plates
at 1×104 cells per well. After 24 hours, cells were in-
cubated with or without 10 mM metformin for an
additional 24 hours. Cells were then trypsinized, re-
suspended in 1×PBS and incubated in 2% trypan blue
for 2 minutes and counted using a haemocytometer
(n = 5 ± SD).Cell cycle analysis
Cell cycle analysis was by flow cytometry as previously
described [27]. Cells were seeded equally in 10 cm dishes
and cultured for 48 hours (~60% confluent). At this
time, the medium was replaced and cells incubated with
or without 10 mM metformin for 24 hours. Control cells
were serum-deprived for 8 hours. Cells were then har-
vested and prepared for analysis using the DNA Prep
Reagent kit according to manufacturers’ instructions
(Beckman Coulter). Briefly, cells were treated with DNA
prep LPR (lysis) solution in order to facilitate propidium
iodide (PI) entry and samples vortexed for 10 seconds
followed by the addition of DNA prep stain (PI and RNAse)
and additional vortexing. Samples were then immediately
analysed on an LSRFortessa™ cell analyser, BD Biosciences.
DNA histograms were analysed using FlowJo v10 software
and the percentage of cells in the G0/G1, S, and G2/M
phase of the cell cycle calculated (n = 3 ± SD).
Cytotoxicity assays
Cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-
2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay. Cells
(8500 cells per well) were seeded into 96-well plates and
after 24 hours exposed to cytotoxic agents for varying
times. After treatment, the medium was replaced with
100 μl of MTT solution (0.5 mg/ml in cell culture medium)
and incubated at 37°C for 2 hours. MTT solution was then
removed, and MTT formazan dissolved in 100 μl dimethyl
sulfoxide (DMSO). Absorbance was measured at 570 nm
using the Bio-Rad iMark microplate reader (n = 3 ± SD).
ICP-MS analysis of platinum-DNA adducts
Inductively-coupled plasma mass spectrometry (ICP-
MS) was performed as previously described [28]. Briefly,
cells were treated with cisplatin (LD30 concentrations)
for 48 hours with or without 24 hour prior exposure to
10 mM metformin. Total genomic DNA was extracted,
resuspended in water and quantified using a NanoDrop
ND-1000 spectrophotometer (Thermo Scientific). DNA
samples were hydrolysed in a final concentration of 1%
HNO3 at 70°C for 24 hours and analysed for platinum
(n = 3 ± SD) on an Agilent 7700 ICP-MS. The instru-
ment was optimised for sensitivity and low oxides. Ana-
lysis was done in no-gas mode, and the instrument was
calibrated for platinum analysis using National Institute
of Standards and Technology traceable standards.
Determination of glycolysis via lactate production
As an indicator of levels of glycolysis, lactate levels in
culture medium were quantified using a lactate dehydro-
genase assay [29] where the production of NADH from
NAD via the conversion of lactate to pyruvate is directly
proportional to lactate concentration. Cells were seeded
and treated as for cell cycle analysis and both conditioned
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were counted using trypan blue exclusion as described
above. For lactate quantification, 50 μl of medium was
added to 950 μl glycine-hydrazine buffer (0.64 M glycine,
0.64 M hydrazine, 4.8 mM NAD+, 16 U/ml lactate de-
hydrogenase, pH 9.2) and incubated at 37°C for 2 minutes.
NADH was then quantified spectrophotometrically at
340 nm and values corrected for cell number (n = 3 ± SD).Figure 1 Anti-proliferative effects of metformin on OSCC cells. A, Cells
number in comparison to untreated controls across all cell lines, n = 4, mea
cytometry analysis (from SNO cells) for untreated cells (Untreated), FCS dep
24 hours (Metformin). Metformin treated cells exhibited an accumulation a
of cells in phase of cell cycle (n = 3, mean ± SD), where for all cells there w
treated cells relative to untreated controls with WHCO1 p = 0.05, WHCO5 pQuantification of reducing equivalents
Total cellular reducing equivalents were quantified by tetra-
zolium (MTT) assay as previously described [30]. An equal
number of cells were seeded into 96-well plates (8500 cells
per well) and after 24 hours cells were incubated for
24 hours with or without 10 mM metformin and MTT
assay performed. Values were corrected for cell number
using trypan blue exclusion as described above (n = 3 ± SD).exposed to 10 mM metformin for 24 hours showed a decrease in cell
n ± SD. B, Quantification and C,representative figures of flow
rived control (FCS Control) and cells exposed to 10 mM metformin for
t the G0/G1 stage of the cell cycle across all cell lines, expressed as %
as a statistically significant increase in cells in G0/G1 in metformin
= 0.04 and SNO p = 0.01.
Figure 2 Effect of metformin on cisplatin and mitomycin C cytotoxicity for OSCC cells. OSCC cells, untreated or treated with 10 mM
metformin for 24 hours and then treated with (A) cisplatin or (B) mitomycin C for a further 48 hours, were assessed by MTT assay. All
metformin-cisplatin treated cells displayed a trend for higher LD50 values, with WHCO1 and SNO cells statistically higher (n = 3, mean ± SD).
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Total low-molecular weight thiols were quantified using
monobromobimane, which forms fluorescent thiol con-
jugates [31]. Cells were seeded and treated as for cell
cycle analysis with or without 10 mM metformin for
24 hours. Cells were subsequently washed three times
with 1×PBS and incubated in 1 ml of 1×PBS with 18 μl
monobromobimane solution (stock 5 mg/ml in DMSO)
for 10 minutes. Cells were then lysed in 1 ml of triple
detergent lysis buffer (50 mM Tris–HCl, 150 mM NaCl,
0.1% SDS, 1% Triton ×-100, 0.5% sodium deoxycholate),
the lysate centrifuged at 10000 g and 100 μl of the re-
sultant supernatant fluorescently analysed at 360nmexcita-
tion/460nmemission using an Ascent multi-well plate
fluorimeter (Thermo Scientific). Cells seeded in parallel
dishes were counted using trypan blue exclusion asTable 1 Cytotoxicity in OSCC cells treated with or without me
Compounds
WHCO1
Cisplatin 70.88 ± 13.8
p = 0.009
11
Met + Cisplatin 126.02 ± 26.57 28
Mitomycin C 32.73 ± 2.49
p = 0.003
32
Met + Mitomycin C 37.15 ± 0.79 30
OSCC cells were treated with 10 mM metformin (Met) and either cisplatin or mitom
(n = 3, mean ± SD).above and fluorescence values were corrected for cell
number (n = 3 ± SD).
Glutathione depletion assay
The glutathione synthesis inhibitor BSO was used in
order to deplete intracellular glutathione levels and
thereby assess the involvement of thiols (glutathione)
in the cytoprotective effects of metformin on cisplatin
toxicity [32]. Cytotoxicity assays were performed as above
with the following modifications, cells were seeded at
7500 cells per well in 96-well plates and allowed to settle
for 18 hours. Cells were then treated with 0.4 mM of BSO
for 18 hours, followed by the addition of 10 mM metfor-
min (or metformin diluent for control cells) and subse-
quently cisplatin, and cytotoxicity determined by MTT
assay as above (n = 3 ± SD).tformin and cisplatin or mitomycin C
LD50 (μM)
WHCO5 SNO
.68 ± 3.62 p = 0.075 11.01 ± 1.62
p = 0.0001
.03 ± 15.81 28.16 ± 3.37
.87 ± 3.03 p = 0.25 9.92 ± 1.80
p = 0.011
.19 ± 4.36 16.64 ± 2.77
ycin C and MTT assays performed. LD50 (μM) was calculated on replicates
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Comparisons were by two-tailed Student’s t-tests and
p < 0.05 was considered statistically significant. LD50
and LD30 values were calculated using GraphPad Prism
version 6.
Results
OSCC cells exhibit decreased cell proliferation and cell
cycle arrest in response to metformin
We investigated the effect of metformin on three OSCC
cell lines (WHCO1, WHCO5 and SNO), previously de-
rived from South African OSCC patients [25,26]. All
cell lines exhibited a significant reduction in cell prolifera-
tion in response to 10 mM metformin after 24 hour treat-
ment, in comparison to untreated controls. There was 50%,
32% and 39% reduction in cell proliferation in WHCO1,
WHCO5 and SNO cells, respectively (Figure 1A). In
addition, we assessed cell cycle progression using flow
cytometry with propidium iodide staining of cellular
DNA content. Cells deprived of foetal calf serum (FCS)
for 8 hours were used as the control, which as expected,
showed an increase in the number of cells in G0/G1
phase of the cell cycle. Metformin treatment (10 mM
for 24 hours), as anticipated, caused an increase in the
number of cells in G0/G1 phase relative to untreated
controls (Figure 1B and C).
Metformin protects cells from cisplatin cytotoxicity
Next, we assessed the effect of metformin on cisplatin
cytotoxicity by MTT assay. Cells pre-treated with
10 mM metformin for 24 hours and then treated with
10 mM metformin and cisplatin for 48 hours (Figure 2A),
exhibited significantly lower cytotoxicity than cellsFigure 3 Decreased platinum-DNA adduct formation in
cisplatin-metformin treated OSCC cells. OSCC cells were treated
with LD30 concentrations of cisplatin, either alone or in combination
with 10 mM metformin. Genomic DNA was extracted and platinum
quantified by ICP-MS which showed a decrease in platinum in
cisplatin-metformin treated cells in comparison to cells treated with
cisplatin alone (values expressed per μg of DNA) (n = 3, mean ± SD).
Figure 4 Metformin increases lactate production, intracellular
NAD(P)H and low molecular weight reduced thiols in OSCC
cells. A, Increased secretion of lactate (per 104 cells) indicated
increased glycolysis levels in OSCC cells treated with 10 mM metformin
for 24 hours in comparison to untreated cells (n = 3, mean ± SD). B,
Elevated total reducing equivalents (per 104cells) in OSCC cells treated
with 10 mM metformin for 24 hours in comparison to untreated cells
(n = 3, mean ± SD). C, Low molecular weight thiols levels (per 104 cells)
is higher in OSCC cells treated with 10 mM metformin for 24 hours, in
comparison to untreated cells (n = 3, mean ± SD).
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LD50 values for cisplatin in the presence of metformin,
with a 78% increase for WHCO1, 140% increase for
WHCO5 and 156% increase for SNO cells (Table 1).
We assessed the effects of metformin on the formation
of cisplatin-DNA adducts, by treating cells as above
but using the calculated LD30 of cisplatin. DNA-bound
platinum, as quantified by ICP-MS, showed a signifi-
cant reduction in metformin treated cells by 19.3% in
WHCO1, 14.1% in WHCO5 and 18.4% in SNO cells
(Figure 3). To determine whether reduced cytotoxicity
and cisplatin-DNA adduct levels was principally due to
the observed metformin-induced reduction in cell pro-
liferation, cells were treated with an alternative DNA
crosslinker, mitomycin C with or without metformin as
above (Figure 2B). Partial to no protection from mito-
mycin C was observed after metformin pre-treatment
across the cell lines (Table 1), indicating that factors
other than decreased proliferation were the major con-
tributors to metformin-dependent cisplatin resistance.
Metformin treatment increases lactate production,
intracellular NAD(P)H and low molecular weight reduced
thiols in OSCC cells
Metformin has been shown to increase cellular glucose
transport and glycolytic rates [33]. We hypothesized that
such an occurrence in OSCC cells could result in an
enhanced intracellular reducing environment (increased
NAD(P)H levels) and the potential for increased intra-
cellular reduced thiol levels, thus contributing to the
observed metformin-induced protection against cis-
platin. Cisplatin cytotoxicity has been previously shown
to be antagonized by low-molecular-weight reduced
thiols via cisplatin-thiol adduct formation, specifically
with glutathione. Glutathione is the major contributor
to intracellular thiols, existing in millimolar amounts in
the cytosol [7,8,34]. We found that glycolysis (as measured
by lactate output), and indirectly, glucose utilization, was
indeed significantly increased for all OSCC cell lines afterFigure 5 Increased intracellular thiols causes cisplatin resistance in O
confirm the role of thiols in cisplatin resistance in OSCC cells. Cells were eit
treated with a concentration range of cisplatin for a further 48. Cytotoxicity
higher LD50 values than cisplatin treated cells alone (n = 3, mean ± SD).treatment with 10 mM metformin for 24 hours relative to
untreated controls (Figure 4A). As predicted, total intra-
cellular NAD(P)H levels (quantified by tetrazolium
(MTT) reduction) (Figure 4B) and low-molecular
weight thiol levels (monobromobimane-thiol adduct
fluorescence) (Figure 4C) were significantly elevated
for all OSCC cell lines following metformin treatment
relative to untreated controls.
Intracellular thiols mediate metformin induced cisplatin
protection in OSCC cells
To confirm that increased thiol levels can protect OSCC
cells against cisplatin, cells were treated with the cell per-
meable thiol derivative, N-acetyl cysteine (NAC) (10 mM)
prior to cisplatin exposure [35]. Predictably, all OSCC
cell lines were significantly protected against cisplatin
cytotoxicity by NAC pre-treatment (Figure 5). Therefore,
our hypothesis, that a metformin-dependent increase in
intracellular thiols is primarily responsible for the ob-
served protection against cisplatin, seemed highly plaus-
ible. Since glutathione is the major thiol species within the
cells, we confirmed its role in metformin-induced cisplatin
resistance using the glutathione synthase inhibitor, BSO
[32], to deplete intracellular glutathione pools. Cells were
treated with metformin in the presence of BSO, prior to
cisplatin exposure. Glutathione depletion by BSO almost
completely reversed the protective effect of metformin
for all OSCC cell lines, confirming the role of reduced-
glutathione in metformin-induced cisplatin resistance
(Figure 6). We also observed that BSO increased cis-
platin cytotoxicity, with lower LD50 values, and this was
anticipated as decreased intracellular glutathione levels
would result in less cisplatin-thiol sequestration and an
increase in cisplatin-DNA adduct formation.
OSCC cells are highly susceptible to copper-bis
(thiosemicarbazones)
Given the above observations, we considered the role of
cytotoxic molecules that are compatible with increasedSCC cells. The cell permeable thiol derivative NAC was used to
her untreated or treated with 10 mM NAC for 24 hours and then
was assessed by MTT assay. All NAC-cisplatin treated cells displayed
Figure 6 Metformin-induced cisplatin resistance is reversed by
glutathione depletion in OSCC cells. The glutathione synthesis
inhibitor, BSO was used to confirm the involvement of elevated
glutathione levels in metformin induced cisplatin resistance in OSCC
cells. MTT assays for cytotoxicity were performed as described, with
cells treated with cisplatin alone (C), or in the presence 0.4 mM BSO
(CB), or metformin and cisplatin (CM), or metformin and cisplatin in
the presence of 0.4 mM BSO (CMB). Data is expressed as the
percentage difference of LD50 values for each treatment relative to
cisplatin alone (n = 3, mean ± SD). Predictably, the inhibition of
glutathione synthesis increased cisplatin toxicity as LD50 values for
cisplatin-BSO treated cells were significantly lower than cisplatin
alone. Importantly, the presence of the inhibitor ablates the protective
effect of metformin, with LD50 values for cisplatin-metfomin-BSO
treated cells approaching those of cisplatin alone.
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used in conjunction with metformin. In this way, the
cytostatic effects of metformin could be utilised when
combined as an adjuvant in chemotherapy regimens;
since there is also evidence that metformin targets can-
cer stem cells, this would offer a considerable added
advantage [18]. The copper bis(thiosemicarbazone) de-
rivatives ATSM and GTSM have been previously shown
to be trapped intracellularly under reducing conditions
[22]. We therefore tested their efficacy as cytotoxic
agents against OSCC cell lines with or without met-
formin. OSCC cells were pre-treated with or without
10 mM metformin for 24 hours and then treated with
copper-bis(thiosemicarbazones) and 10 mM metformin
for 48 hours (Figure 7). Interestingly, we found that
both Cu-ATSM and Cu-GTSM displayed significant
cytotoxicity for all cell lines, both in the presence and
absence of metformin treatment, with LD50 values
lower than or comparable to cisplatin alone. Cu-GTSM
displayed lower LD50 levels than Cu-ATSM (Table 2).
Statistically there was no difference between untreated
and metformin treated samples (p > 0.05). Non-cop
per-conjugated bis(thiosemicarbazone) compounds dis-
played far lower levels of cytotoxicity than their copper-
conjugated counterparts, with LD50 concentrations over
200 μM; copper alone had minimal effect on cells at the
concentrations used in this study.
Discussion
We have established that metformin significantly re-
duces the proliferation of OSCC cells. However, we ob-
served that metabolic alterations caused by metformin
rendered cells less sensitive to the commonly used che-
motherapeutic agent, cisplatin. Previous studies have
shown that metformin can reduce sensitivity to cisplatin
through the activation of pro-survival signals via Akt
[20] and hyperactivation of Akt has been linked to in-
creased glycolysis [36]. Those studies therefore support
our findings, which show that metformin increases
glycolysis with a subsequent increase in intracellular
reducing equivalents and a concomitant increase in
intracellular reduced thiols.
Since cisplatin is ineffective in a reducing intracellular
environment, our findings also support observations re-
garding cisplatin chemoresistance in tumours; cancer
cells within the tumour are known to display a highly
reducing phenotype and resist cisplatin chemotherapy
[37]. However, in recent years, the observation that
tumours consist of cells in differing metabolic states to
surrounding normal tissue [38] has encouraged the con-
cept of cancer-cell specific metabolic targeting as an in-
creasingly popular strategy in cancer therapy [39]. Our
study highlights the use of metformin with cytotoxic
agents that are compatible with or remain active under
Figure 7 Copper bis(thiosemicarbazones) are highly toxic to OSCC cells in the presence of metformin. OSSC cells, untreated or treated
with 10 mM metformin for 24 hours and then treated with (A) GTSM or Cu-GTSM, or (B) ATSM or Cu-ATSM for a further 48 hours were assessed
by MTT assay. The non-copper-conjugated bis(thiosemicarbazones) showed relatively little toxicity with LD50 values greater than 200 μM in both
the presence and absence of metformin. The copper-conjugated compounds however displayed considerable toxicity to OSCC cells with similar
LD50 values for metformin treated-and untreated compounds for WHCO1, WHCO5, and SNO cells.
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therapy combinations for the treatment of this highly
aggressive malignancy.
Mitomycin C, which must be reductively activated to
exert its biological effects [40], is one potential candidate
for this strategy as partial to no protection from this
drug was observed after metformin pre-treatment. How-
ever, an obvious concern with the use of mitomycin C
and related DNA crosslinkers in combination with metfor-
min would be the potential for decreased drug effective-
ness or the emergence of drug resistance in vivo, due toTable 2 Cytotoxicity in OSCC cells treated with or without
metformin and with Cu-GTSM or Cu-ATSM
Compounds LD50 (μM)
WHCO1 WHCO5 SNO
Cu-GTSM 1.14 ± 0.16 5.39 ± 0.9 3.37 ± 0.23
Metformin + Cu-GTSM 1.16 ± 0.12 6.24 ± 0.01 4.23 ± 0.7
GTSM >200 >200 >200
Metformin + GTSM >200 >200 >200
Cu-ATSM 11.93 ± 0.47 13.51 ± 0.81 7.099 ± 0.57
Metformin + Cu-ATSM 12.54 ± 0.19 12.05 ± 0.83 10.90 ± 0.77
ATSM >200 >200 >200
Metformin + ATSM >200 >200 >200
OSCC cells were treated with 10 mM metformin and either GTSM, Cu-GTSM,
ATSM or Cu-ATSM and the MTT assay performed. LD50 (μM) was calculated on
replicates (n = 3, mean ± SD).the anti-proliferative effects of the biguanide. Therefore,
agents that are either reductively activated or tolerant, and
that target proliferating and non-proliferating tumour
cells, would be a more logical choice for use in combin-
ation with metformin in OSCC. We have established
that a potential highly efficacious combination strategy
of this kind, could be metformin and the copper-bis
(thiosemicarbazones), Cu-GTSM or Cu-ATSM. Bis
(thiosemicarbazones) have been considered for cancer
treatment since the 1950’s [23], whilst the copper-bis
(thiosemicarbazones) have been shown to possess po-
tent anti-cancer activities and are attractive candidates
for use as chemotherapeutics as they often preferen-
tially accumulate in tumour tissue and are retained in
cells under reducing conditions [22]. We have shown that
Cu-ATSM and Cu-GTSM, in contrast to non-copper con-
jugated bis(thiosemicarbazones), are highly cytotoxic to
OSCC cells, both in the presence and absence of metfor-
min, and are thus metformin-compatible. The fact that an
increase in toxicity was not observed for Cu-ATSM or
Cu-GTSM in the presence of metformin suggests that: (1)
there already exists a sufficiently high intracellular redu-
cing environment in the OSCC cell lines used (a common
observation in cancer cells [37]) to allow for the intracellu-
lar accumulation of these compounds to toxic levels, and
(2) that the mechanisms of toxicity of these compounds,
are compatible with, but not necessarily dependent on a
intracellular reducing environment.
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http://www.biomedcentral.com/1471-2407/14/314Predictably we found that Cu-GTSM exhibited lower
LD50 values than Cu-ATSM as Cu-GTSM is known to
be rapidly reduced by intracellular thiols resulting in cell
retention, copper release and ultimately apoptosis via
oxidative stress, and/or the inhibition of DNA synthesis
and oxidative phosphorylation [41,42]; Cu-ATSM on the
other hand has been shown to be poorly reduced by
intracellular thiols and thought to be maintained in a
reduced state (and thus retained intracellularly) only
under hypoxic conditions [41]. Recently, however,
Donnelly et al. have shown that Cu-ATSM can be
retained in cells under normoxic conditions when the
intracellular reducing environment is increased due to
factors such as impaired mitochondrial electron trans-
port chain function [22]. These findings appear to
agree with the findings of our study as SNO cells,
which exhibit the greatest intracellular reducing envir-
onment (in the absence of metformin) of all the OSCC
cell lines tested (Figure 4B), exhibit the greatest sensi-
tivity to Cu-ATSM (Table 2). Nonetheless, the fact that
all OSCC cell lines were highly sensitive to Cu-ATSM
alone or in combination with metformin, at LD50
values comparable to or lower than those for cisplatin
for all OSCC cell lines used, is extremely promising
given its increased stability over Cu-GTSM and inves-
tigatory Food and Drug Administration approval of
64Cu-ATSM for use as a hypoxia contrast agent [43].
Conclusions
Metformin, which has an extensive track record and is
well tolerated by individuals, has been shown to sup-
press cancer cell proliferation. We have established that
metformin significantly reduces cell proliferation in
OSCC cell lines. However, we found metformin causes
resistance to cisplatin in OSCC cell lines and as such
we advise that caution be used when administering
cisplatin to diabetic patients treated with metformin
and in the use of metformin as an adjuvant to cisplatin
chemotherapy. Furthermore, we have shown that two
copper-conjugated bis(thiosemicarbazones), Cu-ATSM
and Cu-GTSM, exhibit marked cytotoxicity in OSCC
cells in the presence of metformin. The preliminary
data presented in this study justifies further investiga-
tions into the therapeutic effects of copper-bis(thiose-
micarbazones) in both the presence and absence of
metformin, for OSCC. In addition metformin lends
itself to combination therapy with reduction compat-
ible or activated compounds (unlike cisplatin) for both
OSCC and potentially other cancers where similar
metabolic changes are observed.
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